Clinical efficacy of Lamivudine in therapy of active cirrhosis resulting from chronic hepatitis B

[Objective] To study the clinical efficacy of Lamivudine in the therapy of active cirrhosis resulting from chronic hepatitis B. [Methods] 48 cases of active cirrhosis resulting from chronic hepatitis B were randomly divided into treatment group and control group. Treatment group was treated with Lamivudine 100 mg orally once daily; control group was treated with compound salvia drop pill 10 pills orally three times daily. The course of treatment in both groups lasted one year. Changes in liver function, Child-Pugh score, blood HBV-DNA, HBV markers and serum indexes of hepatic fibrosis were kept under observation. [Results] Early at first detection of HBV DNA after three months treatment, the negative rate was remarkably higher in treatment group than control group(P 0.005). At the end of treatment, all parameters were significantly improved in treatment group compared with those in control group(P 0.05～P 0.001). Liver function, Child-Pugh score and serum hepatic fibrosis indexes were dramatically improved in Lamivudine group compared with baseline parameters (P 0.05～P 0.001), while the control group most parameters showed no remarkable changes except two parameters ALT and PCIII (P 0.05). [Conclusion] Lamivudine treatment is beneficial in patients with chronic hepatitis B induced active cirrhosis due to its effective antiviral and antifibrotic action. It can improve liver function and deter the deteriorating process of active cirrhosis.